SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-072251
Filing Date
2024-08-23
Accepted
2024-08-23 16:35:36
Documents
14
Period of Report
2024-08-22
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea021219701-8k_arcabio.htm   iXBRL 8-K 67153
2 PRESS RELEASE, ISSUED ON AUGUST 23, 2024 ea021219701ex99-1_arcabio.htm EX-99.1 21008
  Complete submission text file 0001213900-24-072251.txt   277566

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abio-20240822.xsd EX-101.SCH 3012
4 XBRL LABEL FILE abio-20240822_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE abio-20240822_pre.xml EX-101.PRE 22357
16 EXTRACTED XBRL INSTANCE DOCUMENT ea021219701-8k_arcabio_htm.xml XML 3658
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 241236781
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)